Analytical Data
-
Gene name
NOVA1
- Application
-
Alternative Names
NOVA1；RNA-binding Protein Nova-1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P51513
-
Expression Region
2-507aa
-
AA Sequence
MAAAPIQQNGTHTGVPIDLDPPDSRKRPLEAPPEAGSTKRTNTGEDGQYFLKVLIPSYAAGSIIGKGGQTIVQLQKETGATIKLSKSKDFYPGTTERVCLIQGTVEALNAVHGFIAEKIREMPQNVAKTEPVSILQPQTTVNPDRIKQTLPSSPTTTKSSPSDPMTTSRANQVKIIVPNSTAGLIIGKGGATVKAVMEQSGAWVQLSQKPDGINLQERVVTVSGEPEQNRKAVELIIQKIQEDPQSGSCLNISYANVTGPVANSNPTGSPYANTAEVLPTAAAAAGLLGHANLAGVAAFPAVLSGFTGNDLVAITSALNTLASYGYNLNTLGLGLSQAAATGALAAAAASANPAAAAANLLATYASEASASGSTAGGTAGTFALGSLAAATAATNGYFGAASPLAASAILGTEKSTDGSKDVVEIAVPENLVGAILGKGGKTLVEYQELTGARIQISKKGEFVPGTRNRKVTITGTPAATQAAQYLITQRITYEQGVRAANPQKVG
-
Molecular Weight
55 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
NOVA1, a member of the NOVA family of proteins, plays a critical role as a neural-specific RNA binding protein involved in regulating alternative splicing and gene expression during neuronal development. Originally identified in the context of neurogenesis, its importance has been highlighted in various neurological disorders, including spinocerebellar ataxia and certain forms of epilepsy. Research has shown that NOVA1 interacts with RNA through specific binding motifs, influencing the splicing decisions of pre-mRNAs and thereby affecting the production of key neuronal proteins. The study of NOVA1 is particularly relevant in understanding the molecular mechanisms underlying neurodevelopmental processes and the pathogenesis of related diseases. Additionally, the exploration of NOVA1 as a therapeutic target is of interest, given its critical regulatory functions in the nervous system. Recombinant NOVA1 protein production allows for in vitro assays to dissect its biochemical properties, interactions with RNA, and the resultant effects on splicing patterns. This research contributes to a broader understanding of RNA regulation in the brain and its implications for neuronal function and dysfunction, paving the way for potential interventions in neurodevelopmental and neurodegenerative diseases.
